Q4 Earnings Forecast for TVTX Issued By HC Wainwright

Key Points

• HC Wainwright reiterated a Buy rating on TVTX with a $57 price target and projects multi‑year EPS growth, forecasting ($0.01) for Q4 2026 and rising to $4.59 EPS by FY2030.
• Travere beat Q1 EPS expectations with $0.05 vs. consensus (~$-0.24) but missed revenue at $127.2M versus ~$136.2M, though revenue grew 55.6% year‑over‑year.
• The stock has a consensus "Moderate Buy" from analysts (10 Buy, 2 Hold, 1 Sell) with an average target of $46.58, while insiders have sold ~310,852 shares (~$11.9M) in the last 90 days.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at HC Wainwright issued their Q4 2026 earnings per share estimates for shares of Travere Therapeutics in a research note issued on Tuesday, May 5th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.01) per share for the quarter. HC Wainwright has a "Buy" rating and a $57.00 price target on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Travere Therapeutics' FY2027 earnings at $0.60 EPS, FY2028 earnings at $2.50 EPS, FY2029 earnings at $3.25 EPS and FY2030 earnings at $4.59 EPS.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a "buy" rating in a research note on Tuesday, April 14th. Wedbush raised their price target on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an "outperform" rating in a research report on Tuesday. Piper Sandler upgraded shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price objective for the company in a research note on Tuesday, April 14th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a report on Wednesday, March 25th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.58.

Travere Therapeutics Stock Down 0.2%

TVTX opened at $44.80 on Wednesday. Travere Therapeutics has a 1-year low of $13.88 and a 1-year high of $48.61. The stock's fifty day simple moving average is $32.31 and its 200 day simple moving average is $32.71. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71. The stock has a market cap of $4.14 billion, a PE ratio of -194.77 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 28.38% and a negative net margin of 4.00%.The business had revenue of $127.20 million for the quarter, compared to analysts' expectations of $136.23 million. During the same quarter in the prior year, the business earned ($0.47) EPS. The firm's revenue for the quarter was up 55.6% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of Travere Therapeutics in the fourth quarter worth $37,000. Torren Management LLC acquired a new stake in Travere Therapeutics in the fourth quarter valued at about $38,000. Comerica Bank boosted its stake in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock valued at $43,000 after buying an additional 492 shares in the last quarter. Fifth Third Bancorp acquired a new stake in Travere Therapeutics in the first quarter valued at about $35,000. Finally, Smartleaf Asset Management LLC boosted its stake in Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock valued at $45,000 after buying an additional 487 shares in the last quarter.

Insider Buying and Selling

In related news, CAO Sandra Calvin sold 21,977 shares of the firm's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total value of $902,595.39. Following the transaction, the chief accounting officer owned 42,353 shares in the company, valued at approximately $1,739,437.71. This trade represents a 34.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 9,100 shares of the firm's stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $39.09, for a total value of $355,719.00. Following the completion of the transaction, the insider owned 113,987 shares in the company, valued at $4,455,751.83. The trade was a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 310,852 shares of company stock valued at $11,890,666 in the last ninety days. Insiders own 4.44% of the company's stock.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Q1 results beat on the bottom line: Travere reported $0.05 EPS vs. consensus (beat) and highlighted key commercial and pipeline milestones (FILSPARI approval in FSGS, record demand for FILSPARI in IgAN, and re‑start of the Phase 3 HARMONY study for pegtibatinase). These execution items support upside to future revenue and valuation. BusinessWire: Q1 Results
• Positive Sentiment: TD Cowen raised its price target to $60 (buy), signaling institutional confidence in longer‑term upside tied to commercialization and pipeline progress. This analyst action is a direct bullish catalyst for the stock. Benzinga: TD Cowen raise
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and a $57 target while slightly trimming multi‑year EPS forecasts (small downgrades to FY2027–FY2030). The firm still models material earnings growth out years, so the note is mixed (maintenance of a buy call but modest near‑term revisions).
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper review of guidance and commercial traction — useful for investors who want management detail and sales cadence. Earnings Call Transcript
• Negative Sentiment: Revenue missed Street expectations ($127.2M reported vs. ~$136.2M expected) and Zacks highlighted the miss and a reported quarterly loss metric — a reminder that top‑line growth must sustain to justify elevated forward targets. Zacks: Q1 Revenue Miss
• Negative Sentiment: Director Roy Baynes sold 9,750 shares under a pre‑arranged Rule 10b5‑1 plan (SEC Form 4 filed). While disclosed as a planned sale, insider selling can create short‑term nervousness for some investors. SEC Form 4

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.